Brief: Exelixis And Natera To Collaborate On Stellar-316, A Phase 3 Pivotal Trial Of Zanzalintinib
07/01/2026 14:07
Jan 7 (Reuters) - Exelixis Inc EXEL.O: EXELIXIS AND NATERA TO COLLABORATE ON STELLAR-316, A PHASE 3 PIVOTAL TRIAL OF ZANZALINTINIB FOR PATIENTS WITH COLORECTAL CANCER EXELIXIS INC - EXPECTS TO INITIATE STELLAR-316 IN MID-2026 Source text: ID:nBwbBkhrRa Further company coverage: EXEL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers